About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Luckypicker - 12 Dec'06 - 12:07 - 14953 of 14956


"john"
12/12/2006 11:53
To
XXX

Subject
Re: Shareholder Question





Hi
As CEO as just returned from the US completing statements
J
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From: XXXX
Date: Tue, 12 Dec 2006 11:51:22
To:"John K Pool"
Subject: Re: Shareholder Question

Dear John

why no RNS??






Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

------------------------------------------------------------------------------------------------------------
-

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

------------------------------------------------------------------------------------------------------------
-
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.





Kind regards

get in now, financials have been completed, results imminent with lots of good news

PH - Could you elaborate on the connection between EIRx patent and the story (above) about Eli Lilly. I have read both of the links that you have given and find no connection between the two.

Eli Lilly are to work on some drugs that they developed that target SURVIVIN.

EIRx have a patent for a means of detecting apoptosis in a cell by detecting changes in the SURVIVIN polypeptide.

There is no suggestion that Eli Lilly are working with EIRx or using their patent.

It's like saying Ferrari have developed a CAR. Skoda make CARs. Oh, hello - Ferrari and Skoda are in partnership!

check the patents, read the email from the chairman, he did not deny the link, to top it all his says the results are ready

PH - Have checked the patents. Yes, they deal with SURVIVIN. But what has that got to do with Eli Lilly. Have checked their website and all recent news items concerning Eli Lilly. Guess what? No mention of EIRx anywhere.

As for the e-mail from 'the chariman':

To the question 'Why no RNS' you got the reply 'As CEO [h]as just returned from the US completing statements'

No mention of any dealings with Eli Lilly. No mention of the link to the news story in the original question to the chairman, so how could he confirm it or deny it. No evidence that this is even a genuine reply from the chairman.

oh dear... we really dont understand the patent issue do we!!!!

check the erx patent list number 7. we also have numerous collaborations vis biofocus which includes ISIS!!!

sort yourself out lad

Mike111D - 12 Dec'06 - 14:06 - 15064 of 15065


Just a quick note to say that yes Survivin does connect back to ERX and they will comment on this as appropriate in due course.

The immediate priority is to get the results RNS out which is imminent, so expect any update on Survivin to follow but only if appropriate.

As commented on by someone else earlier today, CT has literally just returned from the US, so I think you need to allow them 24-48 hours to get their house in order.

PH - Maybe I'm just thick or something. Could you please enlighten me? As I see it (read the patent) EIRx have a patent concerning the polypeptide SURVIVIN. Eli Lilly will be doing some drug trials on SURVIVIN. Where is the tie-up?

Mike just phoned JP himself, and its confirmed, it is ours.. what is wrong with you today

PH I have looked on the ERX website for a break down of the patents with no joy.
I am assuming as ERX hold the Intellectual Property Rights on Survivin any successful production would invoke Patent?

Sorry, PH, but as I said, maybe I'm just being stupid or something. You are gonna have to spell it out for me.

As far as I am aware, SURVIVIN is the name of a particular polypeptide in the same way that Tungsten is the name of a metal. You can't patent that. EIRx's patent relates to a new way of monitoring changes in SURVIVIN to detect the onset of cell apoptosis.

No connection with Eli Lilly as far as I am aware.

And for your delight and delectation, here is the abstract of said patent:

Abstract of WO03091384
The invention provides a method for detecting apoptosis in a myeloid cell comprising detecting an alteration in any one of: i) a Survivin polypeptide having an amino acid sequence as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80 % homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis in neutrophils by modulating Survivin gene expression and a method of treating inflammatory disease by modulating Survivin gene expression of function.

I already posted it here for you

7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

PH - Posted what? Read my post 728, it gives you the abstract of this patent.

I am not having a dispute with you regarding whether or not EIRx have a patent concerning SURVIVIN. That is materially evident.

What I am asking you, and you are deliberately not answering, is what has it got to do with your news link about Eli Lilly? It is a very simple question? Might I suggest that you are afraid to admit that there is no connection whatsoever.

oh please read the news update.. it states they have moved into phase two

PH - Why avoid my question?

Let me spell it out for you (you seem to have difficulty grapsing simple concepts).

1) Today you have posted that there is great news implying a tie-up with a patent owned by EIRx and work being done by Eli Lilly. In fact you even attempted to start two more threads on the subject.

2) EIRx do have a patent that mentions SURVIVIN.

3) Eli Lilly are about to enter phase 2 trials with work on SURVIVIN.

4) SURVIVIN is the name of a polypeptide and is not patented or owned by any one individual or company.

5) Eli Lilly have no tie-up with EIRx and have announced no programme of work with them.

6) Post 722 - EIRx have no partnership with ISIS.


So the news that Eli Lilly has released (via ISIS) has absolutely no bearing on EIRx.

Or am I missing something here, in which case, and as I have previuosly requested, please enlighten us all.

oh for gods sakes..

are you seriously this blind..

YES YES YES

(AP) - In a Dec. 11 story about licensing deals in the biotechnology sector, The Associated Press erroneously named the employer of analyst Eric Ende. He works for Merrill Lynch, not Bank of America. A corrected version of the story appears below.

NEW YORK (AP) -- Last week's licensing deal between Roche Holding AG and Halozyme Therapeutics Inc. potentially worth as much as $581 million over the next 10 years marked another highlight for the biotechnology sector, as analysts predict licensing costs will get steeper.

Related newsJapanese Stocks Fall; Dollar DownInvestors Seek Signs of Robust SpendingMore Jobs in Nov., Unemployment Up Too
Licensing deals between pharmaceutical and biotechnology companies is the norm for the industry, giving development stage companies the money to continue developing products, while larger companies get a chance to bolster their product pipelines.

But with more large companies facing pipeline holes, biotech companies are seeing more money being thrown their way for innovative products, and the deals could lead to future acquisitions.

"That's going to continue to heat up and pick up," said Jason Napadano, senior biotechnology analyst at Zach's Investment Research. "The reason it's happening is that you have these large pharmaceutical companies with an unprecedented number of products going off patent."

That could amount to billions of dollars in losses for some of the major pharmaceutical companies.

The deal last week between Halozyme and Roche calls for the use of Halozyme's drug delivery technology in products being developed by Roche.

Some of the more standard licensing agreements entail the smaller biotechnology company developing the drug with payments from its larger partner, then splitting, in some form, the profits when it hits the market.

Bank of America analyst Eric Ende said in a November report that smaller biotech companies have been seeing higher deal prices as they seek to gain more control over their products. And big pharma has been willing to pay to fill lagging pipelines. The higher licensing prices are partially leading to more expensive buyout deals.

In October, Merck & Co. said it would buy small biotechnology outfit Sirna Therapeutics Inc. for $1.1 billion. Abbott Laboratories is in the process of buying Kos Pharmaceuticals for $3.7 billion.

"Big pharma could start knocking on the door of biotech with market caps of $5 billion," said Morningstar analyst Karen Andersen.

"If you're a pharmaceutical company and you want these products and need these products, biotech can continue to demand these types of big prices," Zack's Napadano said.

By most estimates, the market for licensing deals and pricier acquisitions will continue into 2007. News last week that Pfizer Inc. ended a late-stage program on its experimental heart drug highlighted the company's pipeline problems, with many analysts predicting it will acquire another company, possibly within the next year.

its your last chance to top up now!!!